vs
AMCON DISTRIBUTING CO（DIT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
AMCON DISTRIBUTING CO的季度营收约是Royalty Pharma plc的1.2倍（$730.1M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 0.1%，领先34.3%），Royalty Pharma plc同比增速更快（4.8% vs 2.6%），过去两年AMCON DISTRIBUTING CO的营收复合增速更高（10.1% vs 4.6%）
AMCON Distributing Co是一家总部位于美国的消费品分销企业，主营食品、饮料、美妆个护、烟草及日用百货的分销业务，主要服务美国本土的独立便利店、食品零售商、药店及其他小型零售网点。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
DIT vs RPRX — 直观对比
营收规模更大
DIT
是对方的1.2倍
$622.0M
营收增速更快
RPRX
高出2.1%
2.6%
净利率更高
RPRX
高出34.3%
0.1%
两年增速更快
DIT
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $730.1M | $622.0M |
| 净利润 | $793.0K | $214.2M |
| 毛利率 | 6.6% | — |
| 营业利润率 | 0.5% | 62.4% |
| 净利率 | 0.1% | 34.4% |
| 营收同比 | 2.6% | 4.8% |
| 净利润同比 | 127.6% | 2.9% |
| 每股收益（稀释后） | $1.28 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DITRPRX
| Q4 25 | $730.1M | $622.0M | ||
| Q3 25 | $746.3M | $609.3M | ||
| Q2 25 | $739.6M | $578.7M | ||
| Q1 25 | $619.5M | $568.2M | ||
| Q4 24 | $711.3M | $593.6M | ||
| Q3 24 | $746.3M | $564.7M | ||
| Q2 24 | $717.9M | $537.3M | ||
| Q1 24 | $601.9M | $568.0M |
净利润DITRPRX
| Q4 25 | $793.0K | $214.2M | ||
| Q3 25 | $491.7K | $288.2M | ||
| Q2 25 | $1.3M | $30.2M | ||
| Q1 25 | $-1.6M | $238.3M | ||
| Q4 24 | $348.4K | $208.2M | ||
| Q3 24 | $1.2M | $544.0M | ||
| Q2 24 | $1.5M | $102.0M | ||
| Q1 24 | $539.5K | $4.8M |
毛利率DITRPRX
| Q4 25 | 6.6% | — | ||
| Q3 25 | 6.5% | — | ||
| Q2 25 | 6.7% | — | ||
| Q1 25 | 6.9% | — | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 6.5% | — | ||
| Q2 24 | 6.7% | — | ||
| Q1 24 | 7.0% | — |
营业利润率DITRPRX
| Q4 25 | 0.5% | 62.4% | ||
| Q3 25 | 0.5% | 70.1% | ||
| Q2 25 | 0.7% | 36.3% | ||
| Q1 25 | 0.1% | 94.0% | ||
| Q4 24 | 0.5% | 60.9% | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.8% | 50.2% | ||
| Q1 24 | 0.6% | -13.0% |
净利率DITRPRX
| Q4 25 | 0.1% | 34.4% | ||
| Q3 25 | 0.1% | 47.3% | ||
| Q2 25 | 0.2% | 5.2% | ||
| Q1 25 | -0.3% | 41.9% | ||
| Q4 24 | 0.0% | 35.1% | ||
| Q3 24 | 0.2% | 96.3% | ||
| Q2 24 | 0.2% | 19.0% | ||
| Q1 24 | 0.1% | 0.8% |
每股收益（稀释后）DITRPRX
| Q4 25 | $1.28 | $0.49 | ||
| Q3 25 | $0.80 | $0.67 | ||
| Q2 25 | $2.13 | $0.07 | ||
| Q1 25 | $-2.58 | $0.55 | ||
| Q4 24 | $0.57 | $0.46 | ||
| Q3 24 | $2.02 | $1.21 | ||
| Q2 24 | $2.46 | $0.23 | ||
| Q1 24 | $0.89 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $114.1M | $9.7B |
| 总资产 | $378.7M | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资DITRPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务DITRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | $16.5M | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | $21.8M | $7.6B | ||
| Q2 24 | $23.3M | $7.6B | ||
| Q1 24 | $20.5M | $6.1B |
股东权益DITRPRX
| Q4 25 | $114.1M | $9.7B | ||
| Q3 25 | $113.1M | $9.6B | ||
| Q2 25 | $113.2M | $9.5B | ||
| Q1 25 | $111.4M | $9.8B | ||
| Q4 24 | $112.4M | $10.3B | ||
| Q3 24 | $111.7M | $10.3B | ||
| Q2 24 | $110.0M | $9.8B | ||
| Q1 24 | $108.0M | $9.9B |
总资产DITRPRX
| Q4 25 | $378.7M | $19.6B | ||
| Q3 25 | $391.1M | $19.3B | ||
| Q2 25 | $393.9M | $18.3B | ||
| Q1 25 | $392.0M | $17.6B | ||
| Q4 24 | $404.7M | $18.2B | ||
| Q3 24 | $374.1M | $18.0B | ||
| Q2 24 | $400.6M | $17.7B | ||
| Q1 24 | $336.2M | $16.1B |
负债/权益比DITRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | 0.15× | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | 0.19× | 0.74× | ||
| Q2 24 | 0.21× | 0.78× | ||
| Q1 24 | 0.19× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.7M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-12.4M | — |
| 自由现金流率自由现金流/营收 | -1.7% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | -14.75× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $40.6M | — |
8季度趋势，按日历期对齐
经营现金流DITRPRX
| Q4 25 | $-11.7M | $827.1M | ||
| Q3 25 | $31.1M | $702.6M | ||
| Q2 25 | $-7.0M | $364.0M | ||
| Q1 25 | $34.4M | $596.1M | ||
| Q4 24 | $-39.9M | $742.5M | ||
| Q3 24 | $41.0M | $703.6M | ||
| Q2 24 | $-26.9M | $658.2M | ||
| Q1 24 | $48.8M | $664.6M |
自由现金流DITRPRX
| Q4 25 | $-12.4M | — | ||
| Q3 25 | $30.4M | — | ||
| Q2 25 | $-8.8M | — | ||
| Q1 25 | $31.4M | — | ||
| Q4 24 | $-43.3M | — | ||
| Q3 24 | $37.4M | — | ||
| Q2 24 | $-32.6M | — | ||
| Q1 24 | $41.6M | — |
自由现金流率DITRPRX
| Q4 25 | -1.7% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | -1.2% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | -6.1% | — | ||
| Q3 24 | 5.0% | — | ||
| Q2 24 | -4.5% | — | ||
| Q1 24 | 6.9% | — |
资本支出强度DITRPRX
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.8% | — | ||
| Q1 24 | 1.2% | — |
现金转化率DITRPRX
| Q4 25 | -14.75× | 3.86× | ||
| Q3 25 | 63.32× | 2.44× | ||
| Q2 25 | -5.33× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | -114.43× | 3.57× | ||
| Q3 24 | 33.16× | 1.29× | ||
| Q2 24 | -18.05× | 6.45× | ||
| Q1 24 | 90.37× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DIT
| Cigarettes | $446.5M | 61% |
| Tobacco | $143.7M | 20% |
| Tobacco Food Service And Other | $82.3M | 11% |
| Confectionery | $46.7M | 6% |
| Retail Segment | $10.8M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
